NexGel (NASDAQ:NXGL – Get Free Report) and Avita Medical (NASDAQ:RCEL – Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, analyst recommendations, earnings, risk, institutional ownership, profitability and dividends.
Profitability
This table compares NexGel and Avita Medical’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| NexGel | -51.26% | -121.18% | -41.15% |
| Avita Medical | -56.96% | N/A | -78.53% |
Institutional and Insider Ownership
2.2% of NexGel shares are held by institutional investors. Comparatively, 27.7% of Avita Medical shares are held by institutional investors. 19.8% of NexGel shares are held by company insiders. Comparatively, 2.2% of Avita Medical shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Volatility & Risk
Valuation and Earnings
This table compares NexGel and Avita Medical”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| NexGel | $11.42 million | 0.23 | -$3.00 million | ($0.71) | -0.37 |
| Avita Medical | $71.61 million | 4.74 | -$48.59 million | ($1.44) | -7.65 |
NexGel has higher earnings, but lower revenue than Avita Medical. Avita Medical is trading at a lower price-to-earnings ratio than NexGel, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a summary of current ratings and recommmendations for NexGel and Avita Medical, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| NexGel | 1 | 1 | 0 | 0 | 1.50 |
| Avita Medical | 1 | 1 | 5 | 0 | 2.57 |
NexGel presently has a consensus target price of $2.00, suggesting a potential upside of 652.45%. Avita Medical has a consensus target price of $11.40, suggesting a potential upside of 3.45%. Given NexGel’s higher possible upside, equities research analysts clearly believe NexGel is more favorable than Avita Medical.
About NexGel
NEXGEL, Inc. manufactures high water content, electron beam cross-linked, and aqueous polymer hydrogels and gels. Its products are used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company was formerly known as AquaMed Technologies, Inc. and changed its name to NEXGEL, Inc. in November 2019. The company was incorporated in 2009 and is based in Langhorne, Pennsylvania.
About Avita Medical
AVITA Medical, Inc., together with its subsidiaries, operates as a regenerative medicine company in the United States and internationally. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds, full-thickness skin defects, and repigmentation of stable depigmented vitiligo lesions. It develops RECELL GO to control the manual process of disaggregation, filtration, and soak time. The company was formerly known as AVITA Therapeutics, Inc. AVITA Medical, Inc. was incorporated in 2020 and is headquartered in Valencia, California.
Receive News & Ratings for NexGel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NexGel and related companies with MarketBeat.com's FREE daily email newsletter.
